Soraya Kharboutli



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Inferior Outcomes of EU Versus US Patients Treated with CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use (2023) Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, et al. Journal article CD19-targeted CAR T cells in refractory antisynthetase syndrome (2023) Müller F, Böltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, Reimann H, et al. Journal article Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma (2023) Zundler S, Vitali F, Kharboutli S, Völkl S, Polifka I, Mackensen A, Atreya R, et al. Journal article Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. (2023) Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, et al. Journal article, Erratum Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection (2022) Buecklein VL, Perez-Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, et al. Conference contribution CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients (2022) Müller F, Völkl S, Mougiakakos D, Böltz S, Aigner M, Gary R, Kretschmann S, et al. Conference contribution CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus (2022) Schett G, Böltz S, Müller F, Kleyer A, Völkl S, Aigner M, Gary R, et al. Conference contribution CAR-T CELL TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS- SAFETY AND PRELIMINARY EFFICACY DATA FROM THE FIRST FOUR PATIENTS (2022) Schett G, Böltz S, Müller F, Kleyer A, Völkl S, Aigner M, Gary R, et al. Conference contribution Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus (2022) Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, et al. Journal article CD19-targeted CAR T cells in refractory systemic lupus erythematosus (2021) Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, Böltz S, et al. Journal article